MGI PHARMA Biologics is focused on the creation and development of oncology and acute care products. Located in Lexington, MA, MGI PHARMA Biologics is currently developing two product candidates: amolimogene and ZYC300. Amolimogene is an immune response therapeutic designed to specifically augment the body’s defensive response to human papillomavirus (HPV) for the potential treatment of cervical dysplasia, a precancerous condition. ZYC300 is being developed for solid tumors and hematological cancers.

MGI PHARMA Biologics concentrates on converting genetic information into novel therapeutics. The drug development capabilities and technology platform of MGI PHARMA Biologics will allow the company to develop biologics-based therapeutics.